Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

Camidge, D. Ross; Dziadziuszko, Rafał; Peters, Solange; Mok, Tony; Noé, Johannes; Nowicka, Małgorzata; Gadgeel, Shirish M.; Cheema, Parneet; Pavlakis, Nick; Marinis, Filippo de; Cho, Byoung Chul; Zhang, Li; Moro‐Sibilot, Denis; Liu, Ting; Bordogna, Walter; Balas, Bogdana; Müller, Bárbara; Shaw, Alice T.

doi:10.1016/j.jtho.2019.03.007

articleJournal of Thoracic OncologyMar 20, 2019HYBRID OA

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

DRD. Ross Camidge RDRafał Dziadziuszko SPSolange Peters TMTony Mok JNJohannes Noé

University of Colorado Denver · Gdańsk Medical University · +14 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

INTRODUCTION: At the prior data cutoff (February 9, 2017) the ALEX trial showed superior investigator-assessed progression-free survival (PFS) for alectinib versus crizotinib in untreated, anaplastic lymphoma kinase (ALK)-positive, advanced NSCLC (hazard ratio = 0.47, 95% confidence interval: 0.34-0.65, p

Citation impact

491

total citations

FWCI: 52.93
Percentile: 100%
References: 18

Citations per year

Authors

18

Topics & keywords

Topics

Keywords

Alectinib
Medicine
Lung cancer
Crizotinib
Oncology
Internal medicine
Cancer research

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.